A multi-dose Phase 1b to evaluate the tolerability and PK profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT tablets

Trial Profile

A multi-dose Phase 1b to evaluate the tolerability and PK profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT tablets

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs ADS 4101 (Primary) ; Lacosamide (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 30 May 2017 New trial record
    • 22 May 2017 According to an Adamas Pharmaceuticals media release, topline data from this study are expected in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top